 |
|
Conflicts of Interest and Independent Data Analysis in Industry-Funded Studies
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: I am writing on behalf of the Pharmaceutical Research and Manufacturers of America (PhRMA) in response to the Editorial by Dr Fontanarosa and colleagues1 that discusses a policy that represents a change at JAMA. This change is reflected in the current JAMA Instructions for Authors2:
For all reports (regardless of funding source) containing original data, at least 1 author (eg, the principal investigator) who is independent of any commercial funder should indicate that she or he "had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis." For industry-sponsored studies, this statement must be provided by an investigator who is not employed by any commercial funder, and an independent data analysis must be conducted by statisticians at an academic institution with access to the raw data set, rather than only . . . [Full Text of this Article]
Caroline J. Loew, PhD
cjloew@phrma.org
Pharmaceutical Research and Manufacturers of America
Washington, DC
RELATED ARTICLES
Conflicts of Interest and Independent Data Analysis in Industry-Funded Studies
Geert Molenberghs, Peter Imrey, and Christiana Drake
JAMA. 2005;294(20):2575-2576.
EXTRACT
| FULL TEXT
Conflicts of Interest and Independent Data Analysis in Industry-Funded Studies—Reply
Phil B. Fontanarosa and Catherine D. DeAngelis
JAMA. 2005;294(20):2576-2577.
EXTRACT
| FULL TEXT
Reporting Conflicts of Interest, Financial Aspects of Research, and Role of Sponsors in Funded Studies
Phil B. Fontanarosa, Annette Flanagin, and Catherine D. DeAngelis
JAMA. 2005;294(1):110-111.
EXTRACT
| FULL TEXT
|
